Cefamil-5 600 mg/vial is a Product of the Generic Ceftaroline Fosamil

What Is Cefamil-5 600 mg/vial Indications and Uses?

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by susceptible isolates of the following Gram positive and Gram negative microorganisms- Staphylococcus aureus (including methicillin-susceptible and resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae ... Read more Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by susceptible isolates of the following Gram positive and Gram negative microorganisms- Staphylococcus aureus (including methicillin-susceptible and resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca. Community-Acquired Bacterial Pneumonia (CABP) caused by susceptible isolates of the following Gram positive and Gram negative microorganisms- Streptococcus pneumoniae (including cases with concurrent bacteremia), Staphylococcus aureus, Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella oxytoca and Escherichia coli.

Pharmacology (Source, Chemical and Physical Composition) Of Cefamil-5 600 mg/vial

Cefamil-5 600 mg/vial (Ceftaroline Fosamil) is a cephalosporin with activity against Gram-positive and Gram-negative bacteria. In vitro studies have shown that ceftaroline is bactericidal, due to inhibition of bacterial cell wall synthesis by binding to penicillin binding proteins (PBPs). Ceftaroline is also active against methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-nonsusceptible Streptococcus pneumoniae (PNSP) due to its affinity for the altered PBPs found in these organisms.

Dosage And Administration of Cefamil-5 600 mg/vial

The duration of therapy should be guided by the severity and site of infection and the patient’s clinical and bacteriological progress. Indications Age Range Dosage Infusion Time Duration Acute Bacterial Skin and Skin Structure Infections 18 years and older 600 mg every 12 hours 5 to 60 minutes 5 to 14 days ≥2 years to <18 years (>33 kg) 600 mg every 12 hours 5 to 60 minutes 5 to 14 days ≥2 years to <18 years (≤33kg) 12 mg/kg every 8 hours 5 to 60 minutes 5 to 14 days 2 months to <2 years 8 mg/kg every 8 hours 5 to 60 minutes 5 to 14 days 0 to <2 months 6 mg/kg every 8 hours 30 to 60 minutes 5 to 14 days Community Acquired Bacterial Pneumonia 18 years and older 600 mg every 12 hours 5 to 60 minutes 5 to 14 days ≥2 years to <18 years (>33 kg) 600 mg every 12 hours 5 to 60 minutes 5 to 14 days ≥2 years to <18 years (≤33kg) 12 mg/kg every 8 hours 5 to 60 minutes 5 to 14 days 2 months to <2 years 8 mg/kg every 8 hours 5 to 60 minutes 5 to 14 days

Drug Interactions of Cefamil-5 600 mg/vial

No clinical drug-drug interaction studies have been conducted with Cefamil-5 600 mg/vial (Ceftaroline Fosamil). There is minimal potential for drug-drug interactions between Cefamil-5 and CYP450 substrates, inhibitors, or inducers; drugs known to undergo active renal secretion; and drugs that may alter renal blood flow.

Side Effects of Cefamil-5 600 mg/vial

The common side effects include diarrhea, nausea, vomiting, abdominal pain, headache, dizziness, rash, pruritus, increased transaminases, phlebitis, pyrexia and infusion site reactions (erythema, phlebitis, pain). The uncommon side effects are anemia, leucopenia, thrombocytopenia, hypersensitivity/anaphylaxis, urticaria, Clostridium difficile colitis, prolonged prothrombin time, increased blood creatinine; and rarely eosinophilia.

Precautions And Warnings for Cefamil-5 600 mg/vial

Serious hypersensitivity (anaphylactic) reactions have been reported with beta-lactam antibacterial drugs, including Cefamil-5 600 mg/vial (Ceftaroline Fosamil). If a hypersensitivity reaction occurs, discontinue Cefamil-5. Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including Cefamil-5. Evaluate if diarrhea occurs. Neurological adverse reactions have been reported in patients treated with cephalosporins, including Cefamil-5. If neurological adverse reactions occur, consider discontinuing Cefamil-5 or making appropriate dosage adjustments in patients with renal impairment. If anemia develops during or after therapy, a diagnostic workup for drug-induced hemolytic anemia should be performed and consideration given to discontinuation of Cefamil-5.

Use During Pregnancy and Lactation

No clinical data on pregnancy is available for Ceftaroline. Animal studies with Cefamil-5 600 mg/vial (Ceftaroline Fosamil) do not indicate harmful effects with respect to fertility, pregnancy, parturition or postnatal development. Ceftaroline should not be used during pregnancy unless clearly necessary and only if the potential benefit outweighs the possible risk. It is not known whether Ceftaroline is excreted in human milk, but because many beta-lactams are excreted in breast milk, women who are breast-feeding should be treated with Ceftaroline only if clearly indicated. Interruption of breast-feeding is recommended.

Therapeutic Class

Fifth generation cephalosporins

Storage Conditions of It

Prior to reconstitution, do not store Cefamil-5 powder for infusion above 30°C and should be used immediately after reconstitution. The diluted solution in the infusion bottle should be used within 6 hours when stored at room temperature or within 24 hours when stored under refrigeration at 2° to 8°C Keep away from light and out of the reach of children. Pack Image: Cefamil-5 600 mg/vial IV Infusion Thanks for using MedEx! How would you rate your experience so far?